Combination antifungal therapy: From bench to bedside

Current Infectious Disease Reports

Volumn 10, Issue 6, 2008, Pages 466-472

  Wirk, Baldeep ^b   Wingard, John R ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; MYCOGRAB; PLACEBO; POSACONAZOLE; PYRROLE DERIVATIVE; RAVUCONAZOLE; TERBINAFINE; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; CANDIDIASIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ERADICATION THERAPY; HUMAN; IN VITRO STUDY; INFECTION PREVENTION; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; INVASIVE MYCOSIS; MINIMUM INHIBITORY CONCENTRATION; MUCORMYCOSIS; MYCOSIS; NEPHROTOXICITY; NONHUMAN; REVIEW; SHORT COURSE THERAPY; UNSPECIFIED SIDE EFFECT;

EID: 63249131372     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-008-0076-x     Document Type: Review

References (42)

1. Eliopoulous GM: Synergism and antagonism. Infect Dis Clin North Am 1989, 3:399-406.
2. Mukherjee PK, Sheehan DJ, Hitchcock CA, Ghannoum MA: Combination treatment of invasive fungal infections. Clin Microbiol Rev 2005, 18:163-194.
3. Rex JH, Pfaller MA, Walsh TJ, et al.: Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 2001, 14:643-658.
4. Lewis R, Diekema DJ, Messer SA, et al.: Comparison of E-test, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. J Antimicrob Chemother 2002, 49:345-351.
5. Meletiadis J, Mouton JW, Meis JF, et al.: Colorimetric assay for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol 2001, 39:3402-3408.
6. Meletiadis J, Mouton JW, Meis JF, et al.: Comparison of spectrophotometric and visual reading of NCCLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt, 2,3-bis [2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H tetrazolium-hydroxide] for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol 2001, 39:4256-4263.
7. Klepser ME, Malone D, Lewis RE, et al.: Evaluation of voriconazole pharmacodynamics using time-kill methodology. Antimicrob Agents Chemother 2000, 44:1917-1920.
8. Johnson MD, MacDougall C, Ostrosky-Zeichner L, et al.: Combination antifungal therapy. Antimicrob Agents Chemother 2004, 48:693-715.
9. Steinbach WJ: Combination antifungal therapy for invasive aspergillosis: utilizing new targeting strategies. Curr Drug Targets Infect Disord 2005, 5:203-210.
10. Lewis RE: Decision making in antifungal monotherapy versus combination therapy. Pharmacotherapy 2006, 26:61S-67S.
11. Fohrer C, Fornecker L, Nivoix Y, et al.: Antifungal combination treatment: A future perspective. Int J Antimicrob Agents 2006, 27(Suppl 1):25-30.
12. Kontoyiannis DP, Lewis RE: Combination chemotherapy for invasive fungal infections: What laboratory and clinical studies tell us so far. Drug Resist Updat 2003, 6:257-269.
13. Cuenca-Estrella M: Combinations of antifungal agents in therapy - what value are they? J Antimicrob Chemother 2004, 54:854-869.
14. Pachl J, Suoboda P, Jacobs F, et al.: A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 2006, 42:1404-1413.
15. Petraitis V, Petraitiene R, Sarafandi AA, et al.: Combination therapy in treatment of experimental pulmonary aspergillosis: Synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003, 187:1834-1843.
16. Kontoyiannis DP, Lewis RE: Combination chemotherapy for invasive fungal infections: What laboratory and clinical studies tell us so far. Drug Resist Updat 2003, 6:257-269.
17. Manavanthu EK, Alangaden GJ, Chandrasekar PH: Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus. J Antimicrob Chemother 2003, 51:1423-1425.
18. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH: In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002, 46:245-247.
19. Mosquera J, Sharp A, Moore CB, et al.: In vitro interaction of Terbinafine with itraconazole, fluconazole, amphotericin B, and 5-flucytosine against Aspergillus spp. J Antimicrob Chemother 2002, 50:189-194.
20. Ryder NS, Leitner I: Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species. Med Mycol 2001, 39:91-95.
21. Olson JA, Adler-Moore JP, Smith PJ, Proffitt RT: Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin. Antimicrob Agents Chemother 2005, 49:4895-4902.
22. Barchiesi F, Schimizzi AM, Caselli F, et al.: Interactions between triazoles and amphotericin B against Cryptococcus neoformans. Antimicrob Agents Chemother 2000, 44:2435-2441.
23. Kirkpatrick WR, Perea S, Coco BJ, Patterson TF: Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002, 46:2564-2568.
24. Segal BH, Kwon-Chung J, Walsh TJ, et al.: Immunotherapy for fungal infections. Clin Infect Dis 2006, 42:507-515.
25. Spellberg B, Fu Y, Edwards JE Jr, Ibrahim AS: Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agent Chemother 2005, 49:830-832.
26. Ibrahim AS, Gebermariam T, Fu Y, et al.: The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007, 117:2649-2657.
27. Clemons KV, Stevens DA: Animal models testing monotherapy versus combination antifungal therapy: Lessons learned and future directions. Curr Opin Infect Dis 2006, 19:360-364.
28. Rex JH, Pappas PG, Karchmer AW, et al.: A randomized and blinded multicenter trial of high-dose fluconazole and placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003, 36:1221-1228.
29. Rex JH, Walsh TJ, Sobel JD, et al.: Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000, 30:662-678.
30. Lopez-Ciudad V, Castro-Orjales MJ, Leon C, et al.: Successful treatment of Candida parapsilosis mural endocarditis with combined caspofungin and voriconazole. BMC Infect Dis 2006, 6:73.
31. van der Horst CM, Saag MS, Cloud GA, et al.: Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997, 337:15-21.
32. Brouwer AE, Rajanuwong A, Chierakul W, et al.: Combination antifungal therapies for HIV-associated cryptococcal meningitis: A randomized trial. Lancet 2004, 363:1764-1767.
33. Verweij PE, Donnelly JP, Kullberg BJ, et al.: Amphotericin B versus amphotericin B plus 5-flucytosine: Poor results in the treatment of proven systemic mycoses in neutropenic patients. Infection 1994, 22:81-85.
34. Kontoyiannis DP, Bodey GP, Hanna H, et al.: Outcome determinants of fusariosis in a tertiary care cancer center: The impact of neutrophil recovery. Leuk Lymphoma 2004, 45:139-141.
35. Kontoyiannis DP, Hachem R, Lewis RE, et al.: Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003, 98:292-299.
36. Aliff TA, Masiak PG, Jurcic JG, et al.: Refractory aspergillus pneumonia in patients with acute leukemia. Successful therapy with combination caspofungin and liposomal amphotericin B. Cancer 2003, 97:1025-1032.
37. Kontoyiannias DP, Boktour M, Hanna H, et al.: Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis. Cancer 2005, 103:2334-2337.
38. Marr KA, Boeckh M, Carter RA, et al.: Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004, 39:797-802.
39. Marr KA, Boeckh M, Kim HW: Reply to Cesaro and Visintin. Clin Infect Dis 2005, 40:1075-1076.
40. Singh N, Limaye AP, Forrest G, et al.: Combination of voriconazole and caspofugin as primary therapy for invasive aspergillosis in solid organ transplant recipients: A prospective, multicenter, observational study. Transplantation 2006, 81:320-326.
41. Vazquez L, Mateos JJ, Sanz-Rodriguez C, et al.: Successful treatment of rhinocerebral zygomycosis with a combination of caspofungin and liposomal amphotericin B. Haematologica 2005, 90(Suppl):ECR39.
42. Van Burik JA, Hare RS, Solomon HF, et al.: Posaconazole is effective salvage therapy in zygomycosis: A retrospective study of 91 cases. Clin Infect Dis 2006, 42:e61-e65.